The ongoing conflict in the Middle East is increasingly disrupting global pharmaceutical supply chains. With key air cargo hubs closed and transport routes rerouted, the delivery of life-saving medicines particularly temperature-sensitive cancer drugs is under growing pressure.
The war has forced the closure or disruption of major air transit hubs such as Dubai, Abu Dhabi, and Doha key nodes in global pharmaceutical logistics.
These hubs play a crucial role in connecting Europe, Asia, and Africa, particularly for:
As a result, companies are being forced to rapidly reorganize logistics flows.
Among the most at-risk products are oncology medicines, especially those requiring strict temperature control and rapid delivery.
Key challenges include:
Experts warn that delays could have direct clinical consequences, including treatment interruptions or disease progression.
Pharmaceutical companies are actively seeking alternative routes to maintain supply. Current strategies include:
However, these alternatives come with significant limitations:
Establishing new temperature-controlled logistics corridors “cannot be done overnight,” industry experts emphasize.
The disruption affects more than just the Gulf region. Over 20% of global air cargo for critical medicines is exposed to instability in Middle Eastern airspace.
In addition, indirect risks are emerging:
These cascading effects highlight the fragility of highly optimized, just-in-time pharmaceutical systems.
For now, the pharmaceutical industry is managing to maintain supply through emergency measures and prioritization of critical shipments.
However, experts caution:
Read the full article here.